Altimmune (ALT) Corporate presentation summary

Mission and leadership

• Aims to revolutionize care for serious liver diseases, focusing on unmet medical needs.

• Led by an experienced executive team with backgrounds from major pharmaceutical companies.

Lead asset and clinical focus

• Pemvidutide is a dual glucagon/GLP-1 receptor agonist targeting both metabolic and liver-specific pathways.

• Demonstrated compelling Phase 2 results in MASH, with progression to Phase 3 planned for 2H 2026.

• Also in Phase 2 trials for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), with key data expected in 3Q 2026.

Clinical efficacy and safety

• Pemvidutide showed rapid and sustained reductions in liver fat, inflammation, and fibrosis markers at 24 and 48 weeks.

• Achieved significant weight loss without plateauing and maintained favorable tolerability with low discontinuation rates.

• Demonstrated improvements in non-invasive fibrosis markers (ELF, LSM) and liver enzymes (ALT, cT1).

• Majority of adverse events were mild to moderate, mostly gastrointestinal and occurring early in treatment.